DRG Market Assessment reports

The systemic lupus erythematosus (SLE) therapy market in the United States is largely genericized and off-label. With the exception of GlaxoSmithKline’s Benlysta, AstraZeneca’s Saphnelo and…

Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, transplant…

Fibromyalgia is a chronic condition characterized by pain, tenderness throughout the body, fatigue, and disrupted sleep. Most diagnosed fibromyalgia patients receive prescription drug treatment…

Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…

The treatment of nonalcoholic steatohepatitis (NASH) (also known as metabolic dysfunction–associated steatohepatitis [MASH]) has enormous potential for growth owing to the prevalence of the…

The multiple sclerosis (MS) therapy market continues to evolve, with each new food and drug administration approved disease-modifying therapy (DMT) further expanding treatment choices. The newest…

Clarivate Epidemiology’s coverage of fragile X syndrome (FXS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…

Amyotrophic lateral sclerosis (ALS) is a disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of the muscles and loss of…

Clarivate Epidemiology’s coverage of cutaneous lupus erythematosus (CLE) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

Clarivate Epidemiology’s coverage of retinal vein occlusion (RVO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RVO for…

Although chemotherapy has traditionally been the cornerstone of ovarian cancer treatment, angiogenesis and PARP inhibitors have revolutionized the treatment landscape, impacting prescribing…